Germline variation in NCF4, an innate immunity gene, is associated with an increased risk of colorectal cancer

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1399-1407

  Ryan, Bríd M ^a   Zanetti, Krista A ^a,b   Robles, Ana I ^a   Schetter, Aaron J ^a   Goodman, Julie ^c   Hayes, Richard B ^d   Huang, Wen Yi ^a   Gunter, Mark J ^e   Yeager, Meredith ^f   Burdette, Laurie ^f   Berndt, Sonja I ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Division of Cancer Control and Population Sciences   (United States)

^c GRADIENT   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ATC ^*  (United States)

Author keywords

colorectal cancer; innate immunity; NCF4; single nucleotide polymorphism

Indexed keywords

PROTEIN NCF4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GERM LINE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NCF4 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84891827688     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28457     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2002; 11: 622-9.
3. Huxley RR, Ansary-Moghaddam A, Clifton P, et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 2009; 125: 171-80.
4. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40.
5. Podolsky DK,. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
6. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
7. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007; 50: 839-55.
8. Higaki S, Akazawa A, Nakamura H, et al. Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol 1999; 14: 709-14.
9. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-66.
10. Flossmann E, Rothwell PM,. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
11. Aggarwal BB, Vijayalekshmi RV, Sung B,. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15: 425-30.
12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
13. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-25.
14. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-7.
15. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43: 1066-73.
16. Slattery ML, Wolff RK, Herrick JS, et al. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007; 18: 1095-105.
17. Frank B, Hoffmeister M, Klopp N, et al. Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. Int J Cancer 2010; 127: 2822-30.
18. Zanetti KA, Haznadar M, Welsh JA, et al. 3' UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 2012; 72: 1467-77.
19. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009; 15: 5878-87.
20. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 273S-309S.
21. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst 2005; 97: 989-97.
22. Thorisson GA, Smith AV, Krishnan L, et al. The International HapMap Project Web site. Genome Res 2005; 15: 1592-3.
23. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-20.
24. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
25. Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut 2007; 56: 1585-9.
26. Ferlitsch M, Reinhart K, Pramhas S, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA 2011; 306: 1352-8.
27. Zhan S, Vazquez N, Wientjes FB, et al. Genomic structure, chromosomal localization, start of transcription, and tissue expression of the human p40-phox, a new component of the nicotinamide adenine dinucleotide phosphate-oxidase complex. Blood 1996; 88: 2714-21.
28. Ellson CD, Davidson K, Ferguson GJ, et al. Neutrophils from p40phox-/- mice exhibit severe defects in NADPH oxidase regulation and oxidant-dependent bacterial killing. J Exp Med 2006; 203: 1927-37.
29. Suh CI, Stull ND, Li XJ, et al. The phosphoinositide-binding protein p40phox activates the NADPH oxidase during FcgammaIIA receptor-induced phagocytosis. J Exp Med 2006; 203: 1915-25.
30. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39: 596-604.
31. Roberts RL, Hollis-Moffatt JE, Gearry RB, et al. Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes Immun 2008; 9: 561-5.
32. Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum 2012; 55: 773-7.
33. Eglinton TW, Roberts R, Pearson J, et al. Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. Am J Gastroenterol 2012; 107: 589-96.
34. Muise AM, Xu W, Guo CH, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut 2012; 61: 1028-35.
35. Somasundaram R, Deuring JJ, van der Woude CJ, et al. Linking risk conferring mutations in NCF4 to functional consequences in Crohn's disease. Gut 2012; 61: 1097; author reply 1097-8.
36. Volpp BD, Nauseef WM, Clark RA,. Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science 1988; 242: 1295-7.
37. de Oliveira-Junior EB, Bustamante J, Newburger PE, et al. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol 2011; 73: 420-7.
38. Matsue H, Edelbaum D, Shalhevet D, et al. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 2003; 171: 3010-8.
39. Nakahira K, Kim HP, Geng XH, et al. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med 2006; 203: 2377-89.
40. Hasan N, Pollack A, Cho I,. Infectious causes of colorectal cancer. Infect Dis Clin North Am 2010; 24: 1019-39, x.
41. de Martel C, Franceschi S,. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009; 70: 183-94.
42. Mizuno H, Kitada K, Nakai K, et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009; 2: 18.
43. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138: 958-68.
44. Stirpe F, Della Corte E,. The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). J Biol Chem 1969; 244: 3855-63.
45. Castro GD, de Layno AMAD, Costantini MH, et al. Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer. Toxicology 2001; 160: 11-8.
46. Shaw S, Jayatilleke E,. The role of cellular oxidases and catalytic iron in the pathogenesis of ethanol-induced liver injury. Life Sci 1992; 50: 2045-52.
47. Mira L, Maia L, Barreira L, et al. Evidence for free radical generation due to NADH oxidation by aldehyde oxidase during ethanol metabolism. Arch Biochem Biophys 1995; 318: 53-8.
48. Castro GD, Delgado, de Layno AM, Costantini MH, et al. Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer. Toxicology 2001; 160: 11-8.
49. Goodman JE, Bowman ED, Chanock SJ, et al. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25: 2467-72.